Background: Aldosterone induces cardiac fibrosis in experimental animal models, but only limited information is available on the association between aldosterone and left ventricular (LV) hypertrophy in human beings. The aim of the present study was to determine the role of aldosterone in LV geometry and to investigate other types of target organ damage in hypertensive patients.
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However, it has been shown that LV hypertrophy is not only attributable to the pressure overload, but also to humoral factors, such as angiotensin II and aldosterone. [2] [3] [4] In animal models, both cardiac load and high circulating aldosterone levels stimulate fibrosis within the myocardium, leading to LV hypertrophy. 5, 6 Aldosterone has been demonstrated to influence LV remodeling independent of its impact on systemic BP, as this cardiac fibrosis was prevented by treatment with nonantihypertensive doses of spironolactone, the aldosterone receptor antagonist. 5, 6 These findings in experimental studies are supported by clinical findings demonstrating that serum aldosterone levels are elevated in patients with heart failure, which denote an adverse prognosis. 7 Primary aldosteronism (PA) is the syndrome caused by the autonomous hypersecretion of aldosterone, resulting in a decrease in plasma renin activity (PRA) and an increase in BP. Hypertension with low PRA has been considered to result in fewer cardiovascular complications than other types of hypertension with normal or high PRA, 8 although some previous studies have shown that cardiovascular complications and LV hypertrophy were common even in patients with PA. 9, 10 Patients with renovascular hypertension (RVHT) showed increases in PRA and in their plasma aldosterone concentration (PAC) and plasma angiotensin II concentration, although the PAC is usually higher in patients with PA than in those with RVHT. Previous experimental findings indicate that both angiotensin II and aldosterone participate in the development of hypertensive target organ damage [2] [3] [4] ; however, the differential roles of these peptides in hypertensive target organ damage have not yet been well determined, especially in human beings. Accordingly the aim of the present study was to determine the change in LV geometry and the development of target organ damage in patients with hypertension with different etiologies, namely, essential hypertension (EHT), RVHT, or PA. To keep the BP levels adjusted correctly, 24-h ambulatory BP monitoring was conducted in all subjects.
Methods

Subjects
The study group consisted of hypertensive patients admitted to the Kyushu University Hospital in Fukuoka, Japan. A total of 25 patients with PA caused by Conn's adenoma, 29 patients with RVHT, and 29 patients with EHT were included. In all cases, Conn's adenoma was identified using computed tomography and adrenal vein sampling of the PAC. Surgical treatment was carried out in all patients with PA. Histologic analysis was conducted to confirm Conn's adenoma, and the PAC was normalized in all patients after adrenalectomy. The presence of RVHT was identified with renal scintigraphy, renal angiography, and renal vein sampling of PRA. Of the 29 patients with RVHT, 14 were treated with percutaneous transluminal angioplasty, and their BP was confirmed to have decreased to the normal range. All patients were in sinus rhythm, and none had any valvular or ischemic heart disease.
Of the 25 patients with PA, 12 were treated with antihypertensive agents; 10 of these patients were treated with calcium (Ca) antagonists, one patient with a combination of a Ca antagonist and an ␣-blocker, and one patient with spironolactone. Oral potassium supplementation was used in eight patients. Of the 29 patients with RVHT, 17 were treated with antihypertensive agents, such as Ca antagonists, angiotensin-converting enzyme inhibitors, ␣-blockers, or ␤-blockers. A total of 29 patients with EHT, in whom all possible causes of secondary hypertension had been excluded, were studied as control subjects. All patients with EHT were free of antihypertensive agents. The details of the study protocol were explained to the subjects, and their informed consent was obtained before participation.
Physical and Laboratory Examinations
The 24-h noninvasive ambulatory BP monitoring was performed with ABPM-630 (Nippon Colin Co., Komaki, Japan) or TM-2421 (A&D Co. Inc., Tokyo, Japan). A cuff-oscillometric method was used and the measurement interval was set at 20 min. Daytime (6:00 to 21:00) and night-time (21:00 to 6:00) mean BP were also calculated. Height and weight were measured and body mass index (BMI) was calculated. The BMI was defined as the weight (in kilograms) divided by the height (in meters squared). Spot urine was collected and proteinuria was examined by the tape test method. Hypertensive retinopathy was evaluated by photographs of retina. Blood samples for the PRA and PAC were collected early in the morning, after an overnight rest, and the PRA and PAC were measured by radioimmunoassay, as previously described.
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Echocardiography
All subjects underwent standard M-mode and two-dimensional echocardiography (SSH-160A, Toshiba Co., Tokyo, Japan) with a 3.5-MHz transducer. The LV dimension was measured according to the recommendations of the American Society of Echocardiography. 12 The left ventricular mass (LVM) was calculated according to the formula of Devereux and Reichek 13 :
, where LVEDD is the end-diastolic LV internal diameter, IVSd is the ventricular septal thickness, and PWd is the posterior LV wall thickness. The LVM index was calculated by dividing the LVM by the body surface area. The relative wall thickness (RWT) was calculated at end-diastole according to the following equation: RWT ϭ (interventricular septum thickness ϩ posterior wall thickness)/LV diameter. The LV volume was calculated with the use of the Teichholz formula 14 and an ejection fraction was obtained by the conventional method. Left ventricular hypertrophy, defined as an LVM index Ͼ110 g/m 2 in women and Ն134 g/m 2 in men, 13 was classified as concentric in the presence of an RWT Ն0.45, and as eccentric with an RWT Ͻ0.45. Left ventricular concentric remodeling was diagnosed in the presence of an RWT Ն0.45 and of a normal LVM index.
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Data Analysis
The data are expressed as mean Ϯ SE. Assuming mean values of LVM index of 110 g/m 2 (SD 34) for EHT and of 154 g/m 2 (SD 34) for PA, 16 ,17 the study would have Ͼ90% power (␣ ϭ 0.05) to detect the difference in LVM index by recruiting 17 patients or more in each group. Comparisons among the groups were performed by one-way analysis of variance, followed by the Scheffe's multiple range test. To evaluate the LVM index among the groups, the index was adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, BMI, and duration of hypertension. P values Ͻ .05 were considered to be statistically significant. Table 1 shows the clinical characteristics of the subjects with EHT, RVHT, and PA. Serum potassium concentrations were significantly decreased, and the PAC were significantly increased, in the subjects with PA compared with values in subjects with EHT. In contrast, PRA was significantly increased in the subjects with RVHT. The mean 24-h systolic and diastolic BP were comparable among the three groups. The duration of hypertension was significantly shorter in the patients with RVHT than in those with EHT. Patients with complications of proteinuria or hypertensive retinopathy, as evaluated by the KeithWagener classification, were more common among the patients with RVHT than in those with PA. Sex distribution and age did not differ among the groups.
Results
The results of the measurements of the LV wall thick-ness and dimensions as determined by echocardiography are presented in Table 2 . The end-diastolic interventricular septum thickness was greater in the patients with PA than in those with EHT. The end-systolic and end-diastolic LV diameters did not differ among the three groups. However, the LVM and LVM index were significantly increased in the subjects with PA compared with those with EHT. Moreover, the LVM index was adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, BMI, and duration of hypertension. After adjusting these variables, the LVM and LVM index were significantly (P Ͻ .01) higher in the subjects with PA (243.0 Ϯ 12.3 g and 150.2 Ϯ 7.7 g/m 2 ) than in those with EHT (185.3 Ϯ 11.5 g and 115.2 Ϯ 7.2 g/m 2 ), although the adjusted LVM index in the subjects with PA was not statistically different from that in the subjects with RVHT. The LVM index adjusted AoD ϭ aortic root diameter; CO ϭ cardiac output; EF ϭ ejection fraction; EHT ϭ essential hypertension; FS ϭ fractional shortening; IVSd ϭ end-diastolic interventricular septum thickness; LAD ϭ left atrial dimension; LV ϭ left ventricular; LVEDd ϭ LV end-diastolic dimension; LVEDs ϭ LV end-systolic dimension; PA ϭ primary aldosteronism; PWd ϭ end-diastolic LV posterior wall thickness; RVHT ϭ renovascular hypertension.
Values are mean Ϯ standard error. * P Ͻ .05 vs EHT; P values were determined by analysis of variance.
by these variables was also significantly (P Ͻ .05) increased in the subjects with RVHT (142.3 Ϯ 7.2 g/m 2 ) compared with that in the subjects with EHT. Furthermore, the LVM index significantly correlated with the PAC in the overall combined group of patients with EHT and PA (n ϭ 54; r ϭ 0.271, P Ͻ .05), although this correlation was not found when all three groups were combined (n ϭ 83, r ϭ 0.154; P ϭ .16). Figure 1 and Table 3 indicate the association between the LVM index and RWT among the three groups. The patients with PA had a significantly higher proportion of concentric and eccentric LV hypertrophy than those with EHT.
To evaluate the effect of antihypertensive treatment on the results of the present study, subjects who had been taking antihypertensive drugs were excluded, and the LVM index, after being adjusted for age, sex, mean 24-h systolic BP, mean 24-h pulse rate, BMI, and duration of hypertension, was calculated again. After the exclusions, 29 patients with EHT, 12 patients with RVHT, and 13 patients with PA remained to be studied. The LVM index adjusted by these variables was still found to be significantly higher in the subjects with PA than in those with EHT (149.5 Ϯ 9.4 v 117.7 Ϯ 6.0 g/m 2 ; P Ͻ .05). In addition, the LVM index still significantly correlated with the PAC in the overall combined group of patients with EHT and PA (n ϭ 42, r ϭ 0.363; P Ͻ .05).
Discussion
It was previously reported that hypertensive patients with low PRA, such as those with PA, show fewer cardiovascular complications than patients with other types of hypertension 8 ; however, an accumulation of clinical findings are refuting this idea. 9, 10, 18 In the present study, among the three groups of patients with hypertension, the LVM index adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, BMI, and duration of hypertension, was the highest in the subjects with PA, although the adjusted LVM index did not statistically differ between the patients with PA and RVHT. In contrast, other types of target organ damage, such as proteinuria and hypertensive retinopathy, were more pronounced in the subjects with RVHT despite their significantly shorter duration of hypertension. These findings suggest that hypertensive target organ damage develops in a different manner among patients with different types of hypertension. Pressure overload may not be the only determining factor for hypertensive cardiovascular complications, as BP levels were adjusted by using ambulatory BP monitoring in the present study.
The advantages of the present study over previous studies were that all subjects were examined after admission to the hospital, and BP was evaluated using 24-h ambulatory BP monitoring. It has been shown that ambulatory BP monitoring is superior to casual BP measurements for predicting LV hypertrophy and cardiovascular complications. 19, 20 In the present study, the mean 24-h BP were slightly lower in the patients with EHT. However, even after adjusting the mean 24-h systolic BP, both the LVM and LVM index were still significantly increased in the patients with PA and RVHT compared with those with EHT. In addition, the LVM index of PA showed the highest value among the three groups of hypertension, although the adjusted LVM index did not statistically differ between the patients with PA and RVHT. These EHT ϭ essential hypertension (n ϭ 29); PA ϭ primary aldosteronism (n ϭ 25); RVHT ϭ renovascular hypertension (n ϭ 29). P values were determined by 2 test for comparison with patients with EHT.
findings may support the idea that an excess of aldosterone secretion participates in the progression of LV hypertrophy in human beings. The effect of aldosterone excess on LV hypertrophy in human beings has not yet been well established. 10, 16, 17, [21] [22] [23] Rossi et al showed that LV wall thickness and LVM were increased, and that early diastolic LV filling indexes were decreased, in patients with PA. 10 Furthermore, Tanabe et al demonstrated that LV hypertrophy was more pronounced in the patients with PA than in those with EHT, Cushing syndrome, or pheochromocytoma, 16 although the BP levels were not correctly adjusted in their study. In contrast, other researchers have shown that the development of LV hypertrophy was similar between the patients with EHT and those with PA. 17, 21 The present study demonstrated that LV hypertrophy was more pronounced in patients with PA and RVHT, both of which are accompanied with aldosterone excess in systemic circulation. However, the underlying mechanisms of LV hypertrophy in PA and RVHT is probably slightly different, because the plasma angiotensin II concentration between them is different. It is likely that increased angiotensin II participates in the progression of LV hypertrophy in patients with RVHT.
Angiotensin II type 1 (AT 1 ) receptor stimulation has been shown not only to increase BP but also to mediate cell growth and proliferation of vascular smooth muscle cells, cardiomyocytes, and coronary endothelial cells.
2 Accordingly, AT 1 receptor has been implicated in various cardiovascular, renal, and cerebral pathologic conditions, such as LV hypertrophy, cardiac arrhythmia, atherosclerosis, and glomerulosclerosis. 2 On the other hand, aldosterone primarily acts at renal mineralocorticoid receptors to increase sodium reabsorption. Mineralocorticoid receptors are also present in cardiomyocytes and in the endothelial wall of main coronary arteries, and aldosterone has been shown especially to be involved in cardiac remodeling. 4, 24 It has been established that both angiotensin II and aldosterone are attributable to increase in BP; however, target organ damages caused by these substances should be different. Antihypertensive therapy primarily aims to prevent or reduce target organ damage. The 4E-Left Ventricular Hypertrophy Study was to designed to compare LV mass regression by the selective aldosterone blocker eplerenone to enalapril and the combination of eplerenone and enalapril in hypertensive patients with LV hypertrophy. 25 In that study, it was demonstrated that eplerenon is as effective as enalapril in LV hypertrophy regression, and that the combination of eplerenone and enalapril is more effective in reducing LV mass than eplerenone alone. 25 These results are consistent with the present study and may support the idea that aldosterone and angiotensin II are differentially involved in LV hypertrophy.
The development of hypertensive target organ damage may differ among patients with EHT, PA, and RVHT. Shigematsu et al demonstrated that LV hypertrophy preceded other hypertensive target organ damage, and that eccentric LV hypertrophy was common in patients with PA compared with those with EHT. 26 In the present study, both concentric and eccentric LV hypertrophy were more pronounced in the patients with PA; and these findings were consistent with the findings of Shigematsu et al, in that LV hypertrophy preceded other target organ damage in patients with PA. In contrast, in the patients with RVHT, various kinds of target organ damage seemed to develop in parallel. The patients with RVHT should have high levels of angiotensin II as well as hyperaldosteronism, although the plasma angiotensin II concentrations were not measured in the present study. As it is well established that angiotensin II participates in cell growth or atherosclerosis, 2 an excess of angiotensin II might contribute to the progression of hypertensive target organ damage in patients with RVHT. The present findings may indicate that hypertensive target organ damage develops in a different manner in PA and RVHT, and that this differential progression might be attributable to the different effects of angiotensin II and aldosterone on target organs. The present study included a limited number of subjects; therefore, further studies will be needed to confirm these findings.
In all, 12 of the 25 patients with PA and 17 of the 29 patients with RVHT were treated with antihypertensive agents while the 24-h ambulatory BP monitoring was being conducted. It was difficult to evaluate the effects of antihypertensive agents on the levels of BP in the present study. However, after excluding the patients with antihypertensive agents, the LVM index, adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, BMI, and duration of hypertension was still noted to be significantly higher in the patients with PA than in those with EHT. These findings strongly suggest that antihypertensive medication, in and of itself, had only minimal effects on the results of the present study.
In conclusion, in this study the LVM index, adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, BMI, and duration of hypertension, was found to be increased in the patients with PA and to be significantly correlated with the PAC. The LVM index was also increased in the patients with RVHT. Different kinds of hypertensive organ damage, such as proteinuria and hypertensive retinopathy, seemed to be more pronounced in the patients with RVHT. These findings suggest that aldosterone induces LV hypertrophy in human beings as well as in experimental animals, and that angiotensin II and aldosterone may differentially participate in the development of different types of hypertensive target organ damage.
